Richard B. Lipton, MD

July 13, 2022

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

July 11, 2022

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

July 10, 2022

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

July 08, 2022

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

June 29, 2021

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

June 15, 2021

The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.

June 10, 2021

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

June 08, 2021

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

March 25, 2021

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

March 14, 2021

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.